Prostate Cancer Blog

Impact of Prior Abiraterone Acetate (Zytiga) on Subsequent Activity of Docetaxel (Chemotherapy) in Men with Metastatic Castration-Resistant Prostate Cancer

The explosion of new therapies for men with metastatic castration resistant prostate cancer (mCRPC) raises serious questions about the optimal sequencing of these new treatments as well as whether cross-resistance occurs between these drugs. It was recently reported that chemotherapy with docetaxel (D) is not effective in in men who did not have a ? [...]

By Malecare|2017-10-19T10:48:29-04:00April 1st, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Cross Resistance, Drugs & Treatments, Uncategorized, Understanding APC, Zytiga|0 Comments

Prevalence of Fractures Among Men with Stage IV Prostate Cancer

Many of us believe that the risk developing bone fractures is more common in men who have stage 4 prostate cancer that has developed distant metastasis than those men with stage 4 prostate cancer that do not have distant metastasis. This increased risk, or actually the increase of fractures has significant clinical consequences, such as [...]

By Malecare|2014-03-28T16:51:46-04:00March 28th, 2014|Advanced Prostate Cancer, Bone Mineral Density, Metastases, Uncategorized|0 Comments

Data Links Bisphosphonates and Atrial Fibrillation (AF)

A large meta-analysis of nine studies showed that both oral and IV bisphosphonates were associated with a significantly increased risk of new-onset atrial-fibrillation (AF). The analysis also showed that the risk was greater with the IV drugs. According to the lead author, Dr Abhishek Sharma (Maimonides Medical Center, Brooklyn, NY.) the meta-analysis suggests that bisphosphonates [...]

By Malecare|2014-03-27T13:16:36-04:00March 27th, 2014|Advanced Prostate Cancer, bisphosphonates, Bone Mineral Density, Drugs & Treatments, General Information, Research|0 Comments

CTCs As A Biomarker to Predict Survival in Men with Metastatic CRPC – Can We Be Triaged to Death?

Higher circulating tumor cell counts are associated with an increased risk of death. Men with metastatic castrate resistant prostate cancer don’t have a good biomarker to predict survival. According to a study published online ahead of print in the Journal of Clinical Oncology. by Amir Goldkorn, MD, and colleagues at the Keck School of Medicine of [...]

By Malecare|2020-02-04T11:49:30-05:00March 25th, 2014|Advanced Prostate Cancer, biomarkers, CTCs, Drugs & Treatments, triage, Uncategorized, Understanding APC|1 Comment

Teleconference on Prostate Cancer and Bone Health Tomorrow

Malecare Prostate Cancer Support will present a teleconference titled, "Bone Health and Prostate Cancer.” The conference is scheduled for Tuesday, March 25, 2014 at 6PM ET. The teleconference is available without cost and open to public participation. Simply dial in at 1.800.868.1837 and then enter conference code 156757# (don't forget to press #). 1- Why bone health is [...]

By Malecare|2020-02-04T12:38:12-05:00March 24th, 2014|Advanced Prostate Cancer, Uncategorized|0 Comments

Our Brothers Have Been Dealt a Blow by NICE- They Might Not Approve Xofigo

Officials from the National Institute for Health and Care Excellence (Nice) have made a preliminary decision not to recommend covering the drug radium-223 dichloride (Xofigo) for use for men with prostate cancer that has spread to the bone. This latest draft guidance from Nice states that Bayer has not provided information on how Xofigo performs [...]

By Malecare|2017-10-19T10:48:30-04:00March 24th, 2014|abiraterone acetate, Advanced Prostate Cancer, Alpharadin (radium-223), Drugs & Treatments, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales, Xofigo|1 Comment

Duration of Response to Androgen Deprivation Therapy (ADT) and Efficacy of Secondary ADT, Docetaxel and Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

Men who become castrate resistant in less than 12 months from starting androgen deprivation therapy (ADT) were found to have poor efficacy with a 2nd line of ADT. However, the development of early castrate resistance did not impair the benefit of any of the docetaxel based chemotherapy. Researchers examined the records of 132 consecutive men [...]

By Malecare|2017-10-19T10:48:30-04:00March 21st, 2014|2nd line hormone therapy, Advanced Prostate Cancer, Cabazitaxel, Drugs & Treatments, General Information, Hormone Therapy, Research, Uncategorized, Understanding APC|0 Comments

Tri-weekly Docetaxel Versus Bi-weekly Docetaxel as a Treatment for Advanced Castration Resistant Prostate Cancer: Quality of Life Analysis

Administering chemotherapy using docetaxel (taxotere or T) on a bi-weekly basis with prednisone improved progression free survival and overall survival when compared with the standard tri-weekly schedule for men with advanced castration resistant prostate cancer (CRPC) (Lancet Oncol. 2013;14:117-124). However, quality of life (QoL) differences have not been evaluated. In a trial to evaluate the [...]

By Malecare|2017-10-19T10:48:30-04:00March 20th, 2014|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Understanding APC|2 Comments

Identifying Men at Greatest Risk of Weight Gain from Androgen Deprivation Therapy

Androgen Deprivation Therapy (ADT) or Hormone Therapy (HT) to treat prostate cancer is a mainstay of therapy for men with recurrent or metastatic disease. There are many side effects associated with ADT including weight gain. Weight gain, an adverse metabolic change, may contribute to cardiovascular comorbidity. A better understanding of the risk factors for weight [...]

By Malecare|2017-10-19T10:48:30-04:00March 19th, 2014|Advanced Prostate Cancer, Uncategorized|0 Comments

Application for the FDA Approval of Xtandi in the Pre-Chemo State Has Finally been Submitted

The good news is that finally Astellas and Medivation have submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of XTANDI (enzalutamide) for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. As of today XTANDI is currently only approved for [...]

By Malecare|2014-03-18T11:07:29-04:00March 18th, 2014|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, enzalutamide, FDA, Uncategorized, Xtandi|0 Comments